Leo Wealth LLC Has $1.29 Million Stock Position in Sanofi (NASDAQ:SNY)

Leo Wealth LLC lifted its position in Sanofi (NASDAQ:SNY) by 5.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,669 shares of the company’s stock after buying an additional 1,487 shares during the period. Leo Wealth LLC’s holdings in Sanofi were worth $1,286,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in SNY. Stablepoint Partners LLC increased its holdings in Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after buying an additional 189 shares during the last quarter. Abel Hall LLC grew its position in shares of Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares during the period. PDS Planning Inc increased its stake in shares of Sanofi by 3.1% during the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after purchasing an additional 200 shares during the last quarter. Eagle Ridge Investment Management raised its holdings in shares of Sanofi by 3.8% in the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after purchasing an additional 203 shares during the period. Finally, Financial Advocates Investment Management lifted its stake in Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after purchasing an additional 206 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Price Performance

Sanofi stock opened at $52.87 on Friday. The company has a market capitalization of $134.18 billion, a price-to-earnings ratio of 21.23, a PEG ratio of 1.26 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The stock’s 50 day moving average is $49.62 and its 200-day moving average is $52.35.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. Equities research analysts expect that Sanofi will post 4.34 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.